GuruTrack
BIIB

BIIB

BIOGEN INC

Data as of 2026 Q1 (03-31) · 13F snapshot

Summary
BIOGEN INC (BIIB) is held by 12 tracked hedge-fund managers, a combined reported value of ~$853.32M; the largest are Carl Icahn, Warren Buffett, Steven Cohen. This quarter: 2 added, 3 trimmed. 20 members of Congress have disclosed STOCK Act trades. Data as of 2026 Q1, from public SEC 13F filings, delayed up to ~45 days.
Attention · HighThis quarter · Mixed
Gurus holding12
Congress trades20
Price$200.14vs quarter-end+9.17%
Sectors1
This quarter's moves
New0
Added2
Trimmed / sold3
Top holderCarl Icahn
Carl IcahnHold
Value $235.95M3.5% of portfolio3,215,0512011 Q1
Warren BuffettHold
Value $179.88M0.1% of portfolio643,0222021 Q1
Ken GriffinCALL—
Value $54.98M— of portfolio299,9002026 Q1
Bill Miller—
Value $27.53M— of portfolio79,4932021 Q2
Izzy EnglanderPUT—
Value $19.05M— of portfolio103,9002026 Q1
Ken GriffinPUT—
Value $16.99M— of portfolio92,7002026 Q1
Izzy EnglanderCALL—
Value $15.38M— of portfolio83,9002026 Q1
Michael BurryNew large stake
Value $3.01M2.9% of portfolio10,0002018 Q4
Steven CohenCALL—
Value $861.7K— of portfolio4,7002026 Q1

Insider Trading

Officers · directors · Form 4

  • William A Hawkins

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • SHERWIN STEPHEN A

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Eric K Rowinsky

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Jesus B Mantas

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Susan Langer

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Monish D Patolawala

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Menelas N Pangalos

    Director

    Buy
    2,370 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Menelas N Pangalos

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Lloyd Minor

    Director

    Buy
    1,505 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Maria C Freire

    Director

    Buy
    2,005 @ $0.00Traded 2026-06-09Filed 2026-06-11

  • Adam Keeney

    Head of Corporate Development

    Buy
    939 @ $0.00Traded 2026-05-01Filed 2026-05-05

  • Adam Keeney

    Head of Corporate Development

    Sell$85.1K
    455 @ $187.06Traded 2026-05-01Filed 2026-05-05

  • Sean Godbout

    Chief Accounting Officer

    Buy
    181 @ $0.00Traded 2026-04-01Filed 2026-04-03

  • Sean Godbout

    Chief Accounting Officer

    Sell$9.9K
    54 @ $183.78Traded 2026-04-01Filed 2026-04-03

  • Susan H Alexander

    EVP Chief Legal Officer

    Buy
    8,450 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Singhal Priya

    Head of Development

    Buy
    10,560 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Sean Godbout

    Chief Accounting Officer

    Buy
    1,800 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Christopher Viehbacher

    President and CEO

    Buy
    38,015 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Robin Kramer

    Chief Financial Officer

    Buy
    8,450 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Adam Keeney

    Head of Corporate Development

    Buy
    8,025 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Rachid Izzar

    Head of Global Product Strat.

    Buy
    7,390 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Jane Grogan

    Head of Research

    Buy
    8,450 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Ginger Gregory

    EVP, Human Resources

    Buy
    8,025 @ $0.00Traded 2026-02-13Filed 2026-02-17

  • Nicole Murphy

    Head of Pharm Ops and Tech

    Buy$585
    3 @ $195.03Traded 2026-02-12Filed 2026-02-17

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Data from public SEC 13F & STOCK Act filings, delayed up to ~45 days, partial holdings only — for research, not investment advice.